Governance at a Glance
|Board Members||Audit||Compensation||Nominating and Corporate Governance|
Scott A. Kelly, MD
Dr. Kelly was named Chairman of the Board in December 2018 and has served as a director since April 2017. He is a practicing physician and writer. Dr. Kelly is board certified in Physical Medicine and Rehabilitation. He has served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics' Spine Center since 2007. He is a fellow of the American Board of Physical Medicine and Rehabilitation and a diplomate of the American Academy of Physical Medicine and Rehabilitation. He also is a member of the Spine Intervention Society, Georgia Society of Interventional Spine Physicians, and American Academy of Physical Medicine and Rehabilitation. He has received numerous honors including being named as America's Best Physicians in 2018 by the National Consumer Advisory Board, Leading Physicians of the World in 2018 by the International Association of Healthcare Professionals (IAHCP), America's Most Honored Professionals in 2018 and 2019 by The American Registry, America's Best Physicians in 2016, 2017 and 2018 by The National Consumer Advisory Board, "Top Doctor" in 2015, 2016, 2017, and 2019 by Castle Connolly, and "Top Doctor" by Atlanta Magazine in 2016, 2017 2018, and 2019. He is the author of What I've Learned from You: The Lessons of Life Taught to a Doctor by His Patients. He received his BA in Psychology from Emory University, his medical doctorate from Medical College of Georgia and completed his medical residency at Emory University.
Nader Z. Pourhassan, PhD
Dr. Pourhassan received his Bachelor of Science from Utah State University in 1985, his Masters of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Dr. Pourhassan has authored three books.
His 20 years of business development experience set the stage for him to transform a publicly traded biotech company on the brink of bankruptcy, into a company on the cusp of potentially obtaining FDA approval for its first drug. If granted approval, the drug called leronlimab (PRO 140) could change the treatment paradigms in both HIV and metastatic cancer.
Dr. Pourhassan joined CytoDyn (CYDY) in 2008 as Chief Operating Officer and by September, 2012, was appointed President and CEO. He was responsible for identifying significant opportunities for leronlimab, and single handedly raised enough capital for CytoDyn to complete an acquisition of PRO 140 from Progenics Pharmaceuticals. Dr. Pourhassan has overseen the rapid preclinical and clinical developments of leronlimab (PRO 140) as a therapy for HIV, from Phase 2 development into successful completion of Phase 3 trials. This includes the oversight of the development of trial protocols and interaction with the U.S. Food and Drug Administration (FDA). Dr. Pourhassan also opened the door for exploring leronlimab (PRO 140) for other indications, most notably, he has been involved in the preclinical and clinical developments of leronlimab in indications for triple-negative breast cancer, colon cancer, GvHD, and NASH.
To advance the drug development of leronlimab, Dr. Pourhassan raised capital for CytoDyn of approximately $200 million over the last 5 years.
Carl C. Dockery
Mr. Dockery has been a Director since September 2014. He is a financial executive with years of experience in the insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery is an active investor in various healthcare and early-stage companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery’s 20-year career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. In April 2016, Mr. Dockery became a director of Aytu BioScience, Inc., a publicly traded specialty pharmaceutical company focused on the commercialization of novel products in the field of urology. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.
David F. Welch, PhD
David F. Welch, Ph.D, was appointed a director in January 2019. Dr. Welch co-founded Nasdaq-listed Infinera in 2001, and serves as Chief Innovation Officer and a member of its Board of Directors. He holds over 130 patents in optical transmission technologies, and has authored over 300 technical publications in the same field. In recognition of his technical contributions to the optical industry, he has been awarded the OSA’s Adolph Lomb Medal, Joseph Fraunhofer Award and John Tyndall Award, the IET’s JJ Thompson Medal for Achievement in Electronics, and the IEEE Ernst Weber Managerial Leadership Award. He is a Fellow of the OSA and the IEEE. In 2016, he was elected to the National Academy of Engineering. Dr. Welch holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University.
Jordan G. Naydenov
Mr. Naydenov has been a Director of CytoDyn since June 2009. For more than 20 years, Mr. Naydenov has been actively involved in innovative developments in a variety of fields, ranging from sports, fitness, & health to robotic technology. Since 2001, Mr. Naydenov has served as the Vice President and Director of Milara Incorporated, a leading and multi-faceted company that specializes in wafer-handling robotics, semiconductor systems, and surface mount technologies. In 2006, Mr. Naydenov became the Treasurer of Milara Inc., and additionally began serving as the Director of Milara International, the international representative of Diamond and Equipe brands of Semiconductor Robotics & Systems. Since then, Mr. Naydenov has expanded his experience in innovative developments and industries, with his most recent endeavor beginning in 2017 as the founder of the natural health care product company, Pure Care Pro LLC.
Michael A. Klump
Mr. Klump has nearly 30 years of financial experience and has been actively involved in formulating and executing strategic financial plans. He founded Argonne Capital Group, LLC ("Argonne"), a private investment firm, in 2003. Since inception, Argonne has invested over $750 million of equity in public and private companies spanning multiple industries. In all instances, Argonne looks for opportunities where the firm can leverage its management infrastructure and capabilities to help its portfolio companies with a variety of initiatives, including strategic planning, acquisitions and capital raising. Mr. Klump received a Bachelor of Arts from the University of Colorado in 1987.